Tenecteplase for st elevation myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Jun 2019: Trial registered, NCT03998319
  2. 14 Oct 2021: Trial started, NCT03998319

The trials

NCT03998319: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

State
Under way
Phase
Phase 3
People
445 planned
Started
14 Oct 2021
Primary completion
31 Dec 2024
Arms
Tenecteplase (1/3 systemic weight based dose)
Results
None posted
  1. 26 Jun 2019: Trial registered
  2. 14 Oct 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Low-dose intravenous tenecteplase, Metalyse, Standard-dose intravenous tenecteplase.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.